Wyche Thomas P, Alvarenga René F Ramos, Piotrowski Jeff S, Duster Megan N, Warrack Simone R, Cornilescu Gabriel, De Wolfe Travis J, Hou Yanpeng, Braun Doug R, Ellis Gregory A, Simpkins Scott W, Nelson Justin, Myers Chad L, Steele James, Mori Hirotada, Safdar Nasia, Markley John L, Rajski Scott R, Bugni Tim S
Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison , Madison, Wisconsin 53705, United States.
Yumanity Therapeutics , Cambridge, Massachusetts 02139, United States.
ACS Chem Biol. 2017 Sep 15;12(9):2287-2295. doi: 10.1021/acschembio.7b00388. Epub 2017 Jul 26.
A polyether antibiotic, ecteinamycin (1), was isolated from a marine Actinomadura sp., cultivated from the ascidian Ecteinascidia turbinata. C enrichment, high resolution NMR spectroscopy, and molecular modeling enabled elucidation of the structure of 1, which was validated on the basis of comparisons with its recently reported crystal structure. Importantly, ecteinamycin demonstrated potent activity against the toxigenic strain of Clostridium difficile NAP1/B1/027 (MIC = 59 ng/μL), as well as other toxigenic and nontoxigenic C. difficile isolates both in vitro and in vivo. Additionally, chemical genomics studies using Escherichia coli barcoded deletion mutants led to the identification of sensitive mutants such as trkA and kdpD involved in potassium cation transport and homeostasis supporting a mechanistic proposal that ecteinamycin acts as an ionophore antibiotic. This is the first antibacterial agent whose mechanism of action has been studied using E. coli chemical genomics. On the basis of these data, we propose ecteinamycin as an ionophore antibiotic that causes C. difficile detoxification and cell death via potassium transport dysregulation.
从采自海鞘Ecteinascidia turbinata培养的海洋马杜拉放线菌(Actinomadura sp.)中分离出一种聚醚抗生素ecteinamycin(1)。通过碳富集、高分辨率核磁共振光谱和分子建模确定了1的结构,并通过与最近报道的晶体结构进行比较进行了验证。重要的是,ecteinamycin对艰难梭菌NAP1/B1/027产毒株(MIC = 59 ng/μL)以及其他产毒和无毒艰难梭菌分离株在体外和体内均显示出强效活性。此外,使用大肠杆菌条形码缺失突变体进行的化学基因组学研究导致鉴定出了对ecteinamycin敏感的突变体,如参与钾阳离子转运和体内平衡的trkA和kdpD,这支持了ecteinamycin作为离子载体抗生素的作用机制假说。这是首个使用大肠杆菌化学基因组学研究其作用机制的抗菌剂。基于这些数据,我们提出ecteinamycin是一种离子载体抗生素,它通过钾转运失调导致艰难梭菌解毒和细胞死亡。